Objectives: To assess the extent to which adherence to statins is associated with the incidence of cardiovascular (CV) events and allcause mortality in the primary prevention of CV diseases and whether different analytical approaches influence the observed associations. Methods: This population-based cohort study used data from Finnish registers. The cohort included 97,575 new statin users aged 45 to 75 years in 2001 to 2004 with no CV diseases at baseline. Exposure was defined as adherence to statins (proportion of days covered [PDC]). The primary outcome was any CV event or death during a 3-year follow-up. Different analytical approaches, including multivariable-adjusted Cox regression, inverse probability weighting with time-varying adherence, and propensity score calibration, were used. Results: During the first year of follow-up, 53% displayed good (PDC Z80%), 26% had intermediate (PDC 40%-79%), and 21% exhibited poor (PDC o40%) adherence. After adjustment for sociodemographic and clinical covariates, a 25% relative risk reduction (hazard ratio [HR] 0.75; 95% confidence interval [CI] 0.71-0.79) was observed in the rate of any CV event or death among good versus poor adherers. Good adherers also had a lower incidence than poor adherers of acute coronary syndrome (HR 0.56; 95% CI 0.49-0.65) and acute cerebrovascular disease events (HR 0.67; 95% CI 0.60-0.76). The different analytical approaches achieved comparable results for all the outcomes.
Introduction
Several large randomized controlled trials (RCTs) and metaanalyses have provided convincing evidence for the benefits of statins in the primary and secondary prevention of cardiovascular (CV) events [1, 2] . A recent meta-analysis including 18 RCTs and almost 57,000 high-risk primary prevention patients have demonstrated that statins can reduce the risk of cardiac events by 27% and all-cause mortality by 14% during a median 5 years of follow-up [3] .
In RCTs, the adherence to study medication has generally been good. In real life, however, many patients adhere poorly to preventive medications, such as statins, and the benefits observed in highly adherent RCT populations may not be substantiated. A meta-analysis of 44 epidemiological studies estimated that the prevalence of poor adherence to statins (defined as consuming o80% of the prescribed medication) is as high as 46%, which would translate to 47 excess CV deaths per 100,000 Americans offered statin therapy per year [4] . Only one of the studies, however, included in that meta-analysis investigated the risk of CV events in relation to statin adherence in primary prevention [5] . This observational study found that good adherers had a 20% lower risk of CV events than poor adherers. In fact, some observational studies of primary prevention populations have reported much larger reductions in the risk of CV events (up to $40%) and all-cause mortality (up to 45%) for high versus low levels of statin adherence [5] [6] [7] [8] [9] [10] [11] [12] .
In light of the RCT evidence, the findings of observational studies may exaggerate the risk of CV events and death associated with poor statin adherence. Most of these studies have failed to consider how differences in patients' overall adherence behavior (healthy adherer effect) may affect the results [13] . We therefore assessed the extent to which adherence to statins would be associated with the incidence of CV events and allcause mortality in the primary prevention of CV disease in the general population and whether different analytical approaches for controlling confounding, including the healthy adherer effect, would affect these associations.
Methods
We used data extracted from prescription, special reimbursement, and hospital discharge registers and registers of Statistics Finland (SF). The linkage between the databases was conducted using patient identification numbers. Data were de-identified by the SF after the linkage, and researchers used only de-identified data.
The prescription register is a national electronic pharmacyclaims database maintained by the Social Insurance Institution Finland [14] . The register contains records of all medications reimbursed to community-dwelling residents of Finland, including data on each dispensed medication (e.g., Anatomical Therapeutic Chemical [ATC] classification code [15] , date of prescription, dispensing date, quantity, and costs) and on the patient (e.g., date of birth and death, sex, and place of residence).
The special reimbursement register is also maintained by the Social Insurance Institution. The register includes the records of patients who are entitled to a higher rate of refund because of certain severe or chronic diseases, such as diabetes, hypertension, and coronary heart disease (CHD).
The hospital discharge register maintained by the National Institute for Health and Welfare covers all Finnish hospitals and includes data on discharge diagnoses (the International Classification of Diseases, 10th Revision [ICD-10] codes since 1996), procedure codes, and admission and discharge dates [16] .
The SF compiles data from many administrative sources such as information on marital status and family type from the Population Information System of the Population Register Center [17] . The SF also maintains several registers such as the Register of Completed Education and Degrees.
Study Population
All noninstitutionalized residents of Finland aged 45 to 75 years purchasing statins (ATC codes C10AA01-C10AA07) for the first time between January 1, 2001, and December 31, 2004, were identified. The prescription register contains information since 1994, and a new statin user was defined as a patient who had not purchased any statin since then. Patients whose first statin purchase was cerivastatin (C10AA06, withdrawn from the market in 2001) were excluded from the cohort. In addition, patients who were institutionalized permanently before their first statin purchase were excluded because they are not eligible for drug reimbursement; their drug therapy is provided by the institution and for the most part, it is not recorded in the prescription register. In addition, we used data from a large cohort study for external adjustment for variables not available in the main study (for details, see Appendix in Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.2015.06.002).
A flowchart of the cohort definition is shown in Figure 1 . We wanted to focus on primary prevention patients because the use of statins in individuals with no history of CV diseases has been debated [2, 3, 18] . Therefore, we excluded all secondary prevention patients, that is, patients who had been hospitalized because of CHD (ICD-10 codes I20-I25), cerebrovascular diseases (ICD-10 codes I60-I66, I68, I69, G45, and G46), atherosclerosis (ICD-10 code I70), aneurysm (ICD-10 code I71), heart failure (ICD-10 code I50) or cardiac arrhythmia (ICD-10 codes I46-I49), or any medical procedure related to CHD, cerebrovascular diseases, or peripheral artery disease within the previous three years before cohort entry (index date). In addition, those subjects who had purchased digoxin, antiarrhythmic agents, nitrates, or other cardiac drugs (ATC code C01) within three years before the index date were excluded as potential secondary prevention patients, as were patients who were entitled to special reimbursements for medicines used in the treatment of CHD, cardiac insufficiency, or chronic arrhythmias at the index date or within the first year after it. The one-year time span was included to allow for administrative delays in processing the entitlements. Patients who had purchased lipid-modifying drugs other than statins within three years before the cohort entry were also excluded from the study.
We also excluded patients with mental disorders, organ transplantation, dementia or Alzheimer disease, cancer, or uremia requiring dialysis. These patients were excluded because they often require repeated institutional care and their exposure to statin therapy is therefore potentially misclassified because of incomplete registration of medications used (the prescription register does not include medication use in hospitals or public nursing homes) or because they are not always able to look after and manage their own medications. The exclusion criteria were operationalized by excluding patients who were discharged from hospital with a diagnosis of severe mental disorders, Alzheimer disease, or cancer within three years before the index date, or were entitled to special reimbursement for medicines used in the treatment of severe mental disorders, organ transplantations, Alzheimer disease, cancer, or uremia requiring dialysis at the index date or within the first year after the index date, or patients who purchased antidementia drugs, antipsychotics, or antineoplastic agents within three years before the index date. Patients who had an outcome (CV event or death) or were institutionalized permanently within one year after the index date were also excluded.
Details of all variables used in the cohort definition are reported in Appendix Table 1 in Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.2015.06.002.
No ethics committee approval was required because no patients were contacted during this register-based study. Permissions from the Social Insurance Institution, the National Institute for Health and Welfare, and the SF were obtained to use their register data.
Study Design and Follow-Up
We conducted a retrospective register-based cohort study as outlined in Figure 2 . The index date (t 0 ) is the date of the cohort entry (the date of the first statin dispensation). In the main analyses, exposure was defined as baseline and time-varying cumulative adherence (Fig. 2) . The outcome follow-up started after the first year from the index date and lasted up to three years (t 1t 4 ). The one-year interval between the index date and the start of follow-up was used to allow enough time for the estimation of adherence to be stable. Patients who were institutionalized permanently during the outcome follow-up (t 1t 4 ) were censored at the time of institutionalization.
Exposure
We estimated adherence to statins as the proportion of days covered (PDC), calculated by dividing the number of days covered by statins by the number of days during the period [19] . It was assumed that the dosage would be one tablet per day because previous studies have shown that the prescribed daily dose is one tablet for more than 95% of dispensed statin prescriptions [20, 21] . The same assumption has been used in previous studies on statin adherence in Finland [22, 23] . The patient was credited for the surplus statin from overlapping refills, assuming that the patient had finished the current prescription before starting the refill prescription. Switching between statins was considered as a continuation of therapy. Switching to some lipid-modifying therapy other than statin (C10AB-C10AX) or to fixed combinations (C10B) was considered as discontinuation of therapy.
For the baseline (t 0t 1 ), PDC was estimated for the one year period after the index date. In the time-varying cumulative approach, PDC in the first year (t 0t 1 ) was used as an exposure in the first outcome follow-up period (t 1t 2 ), PDC in the first two years (t 0t 2 ) in the second outcome follow-up period (t 2t 3 ), and PDC in the first three years (t 0t 3 ) in the third outcome follow-up period (t 3t 4 ). Patients were classified into three mutually exclusive groups according to their adherence level: good (PDC Z 80%), intermediate (PDC 40%-79%), or poor (PDC o 40%) adherence [24] .
Outcomes
The primary outcome was "any CV event or death," defined as the occurrence of any of the following: hospital admission for CHD (ICD-10 codes I20-I25) or related medical procedure, cerebrovascular disease (ICD-10 codes I63-I66, I69, G45) or related medical procedure, atherosclerosis (ICD-10 code I70) or medical procedure related to peripheral artery disease, initiation of vasodilators used in cardiac diseases (ATC code C01D), new entitlement to special reimbursements for medicines used in the treatment of CHD, or death from any cause.
In addition to this broad composite outcome, we defined several secondary outcomes: "any CHD event" (ICD-10 codes I20-I25 or related medical procedure), "acute coronary syndrome" (ICD-10 codes I20.0, I21, and I22), "chronic CHD event" (ICD-10 codes I20.8, I20.9, and I25 or related medical procedure), "any cerebrovascular disease event" (ICD-10 codes I63-I66, I69, and G45 or related medical procedure), "acute cerebrovascular disease event" (ICD-10 codes I63, I64, and G45), "chronic cerebrovascular disease event" (ICD-10 codes I65, I66, and I69 or related medical procedure), and "death."
Details of the outcome definition are reported in Appendix Table 2 in Supplemental Materials found at http://dx.doi.org/10. 1016/j.jval.2015.06.002. Patients who had an outcome during the follow-up period (t 1t 4 ) were censored at the time of the outcome event under study (e.g., any CHD event).
Confounders
To control for potential confounding in the analyses, we obtained information on sociodemographic factors and cardiac and non- Fig. 2 -Study design. In the analyses exposure was estimated using three alternative approaches: In the unadjusted and multivariable adjusted models as baseline adherence from the index date to the end of first year of follow up (t0-t1); in the inverse probability weighted analyses as a time varying adherence from the index date until the end of pre-event (CVD-event or death) year or the end of follow-up (t0-t1 or t0-t2 or t0-t3) which ever occurred first; and in the sensitivity analyses from the year preceding the event or end of follow-up (t0-t1 or t1-t2 or t2-t3). PDC, proportion of days covered. (Color version of figure is available online.) cardiac comorbidity (see details in Appendix Table 3 in Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.2015.06. 002). The covariates were identified on the basis of literature [25] , expert opinion, and availability of covariates within the data.
The sociodemographic factors were measured for the year of the index date. These variables included sex, age, region of residence (hospital district), socioeconomic group (the SF variable), taxable income, level of education, type of main activity, marital status, and family type.
The cardiac comorbidity factors and drug therapy included special reimbursements for dysfunctions of lipid metabolism, diabetes, or hypertension; hospitalizations for dysfunction of lipid metabolism, diabetes, or hypertension; type and intensity of the initial statin therapy, dispensation delay (time elapsed between prescription and dispensation of the first statin [23] ), year of statin initiation, baseline drug therapy of diabetes and CV diseases (ATC codes A10A, A10B, B01, C03, and C07-C09), and the number of concurrent CV medications. The intensity of statin therapy was defined according to average expected low-density lipoprotein cholesterol response to a specific statin and dose (modified from Stone et al. [26] ).
The noncardiac comorbidity factors included the following: special reimbursements for Parkinson disease, rheumatoid arthritis, asthma, and chronic obstructive pulmonary disease; hospitalizations for Parkinson disease, rheumatoid arthritis, certain diseases of the nervous system, depression, respiratory diseases, renal impairments, obesity, retinopathy, polyneuropathy, sleep apnea, psoriasis, and alcoholism/narcomania, and number of hospital days within 365 days before the index date; purchasing of antidepressants, drugs for obstructive airway diseases, nonsteroidal anti-inflammatory drugs, and corticosteroids for systemic use within 365 days before the index date; and total medication costs in the 120 days preceding the index date.
Continuous covariates (taxable income, total medication costs, dispensation delay, the number of concurrent CV medications, and number of hospital days) were categorized to allow for possible nonlinear associations.
Specifically, inclusion of a wide range of measures of socioeconomic status and dispensation delay as confounders was postulated to improve the control for the healthy adherer effect. Previous research has shown a consistent direct association of low socioeconomic status with poor adherence [27, 28] as well as with CV disease and mortality [29] . We considered a dispensation delay as a proxy for overall adherence behavior because it was associated with the outcomes (data not shown) but this association cannot be due to any effect of the statins.
Statistical Analyses
In the main analyses, we fitted three types of Cox proportional hazards models: unadjusted, multivariable-adjusted, and inverse probability weighted (IPW) models. We also conducted additional subgroup and sensitivity analyses to test the robustness of our results.
Baseline characteristics were compared between the adherence groups using standardized difference of the mean. Standardized difference of the mean has a minimum value of zero, meaning that there is no difference between the two compared categories. A value larger than 0.1 implies that there might be a meaningful imbalance between the categories [30] .
Unadjusted and multivariable-adjusted analyses
We used Cox proportional hazard models to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) associated with the baseline adherence group (good or intermediate vs. poor). We adjusted for all sociodemographic, cardiac, and noncardiac comorbidity factors listed above and in Appendix Table 3 . In these analyses, exposure was the baseline (t 0t 1 ) adherence.
IPW analyses
We estimated the HRs and 95% CIs associated with time-varying cumulative adherence with a weighted Cox proportional hazard model with robust standard error estimates. Time-varying adherence was handled in the Cox model by the counting process method [31] . We used weighting to account for differences in baseline characteristics between the three adherence groups. Stabilized inverse probability weights were based on propensity scores (PS). We used a multinomial logistic regression model to estimate the PS. In the PS model, the baseline adherence group was the dependent variable. Independent variables to be included in the PS model were selected from all available confounders on the basis of their association with the outcome using P value less than 0.1 as the selection criterion. The balance between adherence groups both in the actual study population and in the weighted population was assessed with standardized difference of the means.
Subgroup and sensitivity analyses
We also performed exploratory subgroup analyses by sex (male/ female), age (o65/Z65 years), and intensity of statin therapy (low, moderate). In the sensitivity analyses, alternative thresholds for adherence (PDC o30%/30%-70%/Z70% and o80%/Z80%) were used. In addition, IPW analyses with time-varying annual adherence were conducted.
The assumption underlying the healthy adherer effect is that patients who adhere to preventive medications are more likely to seek other preventive services and to have a healthier lifestyle than do nonadherers in terms of smoking habits, diet, physical activity, alcohol consumption, and other risky behaviors [32] . Therefore, we used an external adjustment method called PS calibration to examine whether differences in unmeasured lifestyle factors (body mass index, smoking, alcohol use, physical activity) and self-reported health, available to us from an external validation study, could explain the observed associations in the subgroup younger than 65 years (see Appendix in Supplemental Materials).
All analyses were conducted using SAS software (version 9.3; SAS Institute, Inc., Cary, NC).
Results

Characteristics of the Study Population
A total of 97,575 primary prevention patients were included in the analyses. The demographic and clinical characteristics of the cohort are presented in Table 1 . The mean age of the cohort was 59 years, and 44% of the cohort was men. In total, 53% of the patients displayed good (PDC Z 80%), 26% intermediate (PDC 40%-79%) and 21% poor (PDC o 40%) adherence during the first year of follow-up. More detailed descriptions of the patient population and the annual transitions of patient adherence levels are provided in Appendix Table 4 and Appendix Figure 1 in Supplemental Materials found at http://dx.doi.org/10.1016/j.jval. 2015.06.002. The baseline characteristics were well balanced between the three adherence groups. Individuals with good adherence appeared, however, to be older, less likely to be divorced, have hypertension, purchase more drugs, have higher drug costs, and purchase their first statin prescription sooner than did individuals with poor adherence.
Unadjusted and Multivariable-Adjusted Analyses
In total, 9002 individuals (9.2%) experienced an outcome (CV event or death) during the follow-up period (t 1t 4 ). The incidence of any CV event or death was 38.2/1000 patient-years at risk in the poor adherence group, 33.2/1000 in the intermediate adherence group, and 29.5/1000 in the good adherence group (Table 2) . Between the good and poor adherence groups, there was an absolute reduction of 8.7/1000 person-years in the rate of any CV event or death during the follow-up. The respective relative risk (RR) reduction was 23% (unadjusted HR 0.77; 95% CI 0.73-0.81).
The other outcomes occurred in fewer patients and thus smaller absolute risk reductions were observed for those outcomes. The hazard for acute coronary syndrome was reduced by 42% (unadjusted HR 0.58; 95% CI 0.50-0.66), for acute cerebrovascular disease event by 29% (unadjusted HR 0.71; 95% CI 0.63-0.80), and for death from any cause by 27% (unadjusted HR 0.73; 95% CI 0.64-0.84). The estimates from the multivariable-adjusted models did not appreciably differ from the unadjusted estimates.
IPW Analyses with Time-Varying Adherence
The IPW adjustment improved the balance between the adherence groups (see Appendix Table 4 in Supplemental Materials). The IPW analyses with time-varying cumulative adherence, however, provided comparable results to the unadjusted and multivariable-adjusted analyses. The results of IPW analyses with time-varying cumulative adherence are described in Table 2 .
Subgroup and Sensitivity Analyses
The relative effect of adherence was similar in the subgroup analyses as observed in the overall study population ( Table 3) .
Because of smaller incidence of CV events and death, however, the magnitude of absolute treatment effect was smaller among women than among men as it was in younger subjects (o65 years) when compared with older (Z65 years) patients.
The results of sensitivity analyses using alternative thresholds and timing of adherence assessment are reported in Table 4 . The findings of the sensitivity analyses are similar to those in the preceding unadjusted, multivariable-adjusted, and IPW analyses.
Finally, external adjustment for lifestyle factors and selfreported health that remained unmeasured in the main study had no appreciable effect on the association between adherence and the risk of CV events or death observed in the population younger than 65 years (see Appendix in Supplemental Materials). In this age group, the unadjusted HR for any CV or death associated with good adherence in comparison with poor adherence was 0.73 (95% CI 0.68-0.78) ( Table 3 ). In the sensitivity 
Discussion
Our study detected an approximately 30% increase in the risk of any CV events or death among primary prevention patients who adhere poorly to statins when they were compared with good adherers. According to our findings, poor adherence (PDC o40%) might lead to nine excess CV events and deaths per 1000 patientyears in comparison with good adherence (PDC Z80%). The different analytical approaches for controlling confounding and healthy adherer effect using multivariable-adjusted and IPW Cox regression as well as PS calibration had little impact on the results. Furthermore, the sensitivity analyses using different thresholds and time periods for adherence measurement provided comparable results to those found in the main analyses. In addition, the results of the subgroup analyses, concerning the direction of the effect of adherence, are in line with the results of the overall study population. The impact of statin adherence on clinical outcomes has been evaluated much more extensively in secondary than in primary prevention populations [4, 13, 33] . In primary prevention, three nested case-control studies of Canadian statin users [8, 10, 11] , an Italian cohort study [5, 9] , and two cohort studies from Israel [6, 7] have been published. Our findings that good adherence to statins is associated with a reduction in the risk of CV events are in line with the results of these primary prevention studies. Any direct comparison of the effect sizes of our study and the previously published studies, however, is complicated by differences in the definition of the primary prevention status, adherence, and outcomes. In their studies, the Canadian researchers reported a reduced risk of nonfatal CHD events (RR 0.81; 95% CI 0.67-0.97) among those with a high level of adherence (medication possession ratio Z90%) than among those with lower levels of adherence (o90%) during a short-term follow-up (up to 3.5 years) [8] . Two other studies with up to 6.5 years of follow-up [10, 11] indicated that a high level of adherence (medication possession ratio Z 80%) reduced the risk of CHD (fatal and nonfatal) by 18% (RR 0.82; 95% CI 0.77-0.87) and that of cerebrovascular events by 26% (RR 0.74; 95% CI 0.65-0.84) when compared with low adherence (o20%). In an Italian study, Corrao et al. [9] reported that high adherence (PDC 475%) was associated with a 19% reduction in the risk of ischemic heart disease events (HR 0.81; 95% CI 0.71-0.95) compared with low adherence (r25%). Finally, in the study of Shalev et al. [6] , a 42% lower risk of major coronary events including myocardial infractions and cardiac revascularization procedures (RR 0.58; 95% CI 0.55-0.62) was reported among adherent patients (PDC Z80%) compared with nonadherent users (PDC o20%). The results of the present study on the risk of acute coronary syndrome are consistent with those of the Israeli study considering the differences in the reference groups and outcome definitions.
Because patients in observational studies are not randomly assigned to the exposure groups, the observed differences in outcomes between adherence groups may be due to differences in the patients' overall adherence behavior, including lifestyle, and other unmeasured confounders rather than differences in their exposure to statins [32, 34] . According to the review of Bitton et al. [13] on the impact of medication adherence on the risk of CHD, all primary prevention studies have failed to consider how this healthy adherer effect affects their results, and only a few secondary prevention studies [24, 35, 36] have attempted to control for this phenomenon. We attempted to reduce the healthy adherer bias in two ways: 1) by including several measures of socioeconomic status as well as dispensation delay, the difference between the dates of prescribing and filling the first statin prescription, as a proxy for overall adherence behavior in our multivariable models, and 2) by using PS calibration [37, 38] . The PS calibration is a novel approach used in pharmacoepidemiologic database studies that lack information on various confounders [38] . Although the different analytical approaches and various sensitivity analyses increase our confidence in our results, we cannot rule out the possibility that they are partly due to the healthy adherer effect.
Our study has several strengths. First, in the main study, we used a larger number of covariates to adjust our models than had been included in any of the previously published primary prevention studies such as a larger set of socioeconomic variables (such as marital status and income). Second, we used a cohort of incident statin users. Because prevalent users might be more tolerant and adherent than incident users to the medication under study, the inclusion of prevalent users in observational studies may bias the results and exaggerate the effects of statins and other health care interventions [39] . Third, adherence was handled also as time-varying exposure in the analyses to provide a more accurate measure of adherence over the whole follow-up [12] . Finally, our study was based on total population and included all new statin users living in Finland. The Nordic countries are particularly favorable settings for undertaking these kinds of pharmacoepidemiological studies because they have single universal prescription reimbursement systems with fully or nearly fully comprehensive prescription registers [14] .
Our study also has limitations. First, we did not have data on some potentially important confounders such as cholesterol levels, blood pressure, and health behavior. In the sensitivity analyses, we attempted to mitigate this problem by the PS calibration that included lifestyle factors and self-reported health. Second, we did not consider time-varying confounders. Third, because the analyses were based on register data, some misclassification in the measurement of exposure, confounders, and outcomes is likely to exist. For example, we only had information on drug purchases, that is, no way of determining whether the individuals actually used the statins they purchased. Fourth, the outcome follow-up time was relatively short. The final linking of data was conducted by the SF and at this stage, the patient identification numbers were deleted from the data. Thus, we were unable to update the data with more current information on CV events and deaths. Because we did not have data on CV mortality, we could not include the commonly used end point of fatal CV events in our analyses [40] . Furthermore, our study concentrated on the benefits of statin therapy in CV disease prevention; however, those with better adherence to statins may have a greater risk of adverse outcomes such as new-onset diabetes than do those with poor adherence [41] . Finally, healthier individuals are more likely to survive and remain longer in the follow-up. Because those individuals who adhere to therapy seem to have a healthier lifestyle and may be healthier than nonadherers, this may have led to a selection bias that was not accounted for in our analyses. Our study cohort included patients who purchased their first statin between 2001 and 2004. Since then, several changes have occurred that may influence adherence to drug therapy and applicability of our results. First, the availability of generic products has led to price competition and lowered the costs of all statins. Previous statin studies have shown that lower out-ofpocket costs are associated with better adherence [23, 42] . Even though the rates of adherence might have changed over time, however, we do not expect this to have affected the association between adherence and CV events and all-cause mortality. Second, in our study, statin therapy was typically started either with simvastatin or with atorvastatin. In October 2006 in Finland, the reimbursement of the more expensive atorvastatin and rosuvastatin was restricted to the treatment of severe disorders of lipid metabolism in high-risk patients who could not tolerate less expensive statins. In 2007, statin therapy was typically initiated with 10-or 20-mg simvastatin tablets (24% and 52% of the initiators, respectively) [43] . Even though these restrictions are no longer implemented, more patients use simvastatin now than did during our study period [44] . In our study, 70% of the study population initiated therapy with a moderate-intensity statin (e. g., simvastatin 20-40 mg or atorvastatin 10-20 mg). In our analyses, which were stratified by the intensity of statin therapy, a larger RR reduction was observed among the subgroup initiating with moderate-intensity therapy than among those initiating with low-intensity therapy. On the basis of this finding, we would expect a shift toward higher-intensity therapy to lead to larger benefits with good adherence than those that were observed here.
In conclusion, we used different analytical approaches to control for confounding by a large number of potential confounders and consistently found evidence for large protective effects attributable to adherence on CV morbidity and all-cause mortality. Our findings support the need for physicians, pharmacists, and other health care professionals to highlight the importance of adherence to all patients taking statins. Even though there appears to be a need to implement systematic interventions that support adherence [45] , it is important to assess the effectiveness, costeffectiveness, and budget impact of such interventions, especially in primary prevention populations. This need is highlighted by the large number of individuals using statins in the primary prevention of CV diseases and the possibility to enhance the expected benefits and cost-effectiveness of these interventions by targeting the programs to high-risk patients in primary prevention.
